At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Buspirone +1 moredrug
Likely dose
Buspirone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Ventilatory Capacity in Those With Chronic High Level SCI
In Brief
A Phase 2 clinical trial evaluating Buspirone and Placebo for Spinal Cord Injuries. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartNov 2020
First PostedSep 2021
Primary CompletionNov 2024
TodayJul 2026
First PostedSep 13, 2021
Enrollment StartNov 29, 2020
Primary CompletionNov 1, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 4.8 years ago
Interventions
Buspironedrug
Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
Placebodrug
Subjects take placebo pills (twice a day) for 14 Days.